These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8204504)

  • 1. Antisense catalytic RNAs as therapeutic agents.
    Castanotto D; Rossi JJ; Sarver N
    Adv Pharmacol; 1994; 25():289-317. PubMed ID: 8204504
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.
    Smythe JA; Symonds G
    Inflamm Res; 1995 Jan; 44(1):11-5. PubMed ID: 7664023
    [No Abstract]   [Full Text] [Related]  

  • 5. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
    Rossi JJ; Sarver N
    Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448
    [No Abstract]   [Full Text] [Related]  

  • 6. Antisense treatment of viral infection.
    Whitton JL
    Adv Virus Res; 1994; 44():267-303. PubMed ID: 7817875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense technology for cancer therapy: does it make sense?
    Carter G; Lemoine NR
    Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718
    [No Abstract]   [Full Text] [Related]  

  • 8. Antisense DNA and RNA strategies: new approaches to therapy.
    Gibson I
    J R Coll Physicians Lond; 1994; 28(6):507-11. PubMed ID: 7884705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antisense sequence of the HIV-1 TAR stem-loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates.
    Pérez-Ruiz M; Sievers D; García-López PA; Berzal-Herranz A
    Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):33-42. PubMed ID: 10192287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.
    Homann M; Tzortzakaki S; Rittner K; Sczakiel G; Tabler M
    Nucleic Acids Res; 1993 Jun; 21(12):2809-14. PubMed ID: 8332489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA as a target for developing antivirals.
    McKnight KL; Heinz BA
    Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear antisense RNA. An efficient new method to inhibit gene expression.
    Liu Z; Carmichael GG
    Mol Biotechnol; 1994 Oct; 2(2):107-18. PubMed ID: 7532538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering genomics. RNA antagonists--a new class of antisense drugs.
    Orum H
    IEEE Eng Med Biol Mag; 2005; 24(4):81-7. PubMed ID: 16119218
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene therapy for HIV.
    Lever AM
    Sex Transm Infect; 2001 Apr; 77(2):93-6. PubMed ID: 11287684
    [No Abstract]   [Full Text] [Related]  

  • 16. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of functional RNAs in human diseases].
    Tanaka Y; Kozu T
    Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2235-7. PubMed ID: 17471945
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular therapeutic strategies in hepatitis B virus infection.
    Offensperger WB; Blum HE; Gerok W
    Clin Investig; 1994 Oct; 72(10):737-41. PubMed ID: 7865975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes.
    Nash KL; Alexander GJ; Lever AM
    J Viral Hepat; 2005 Jul; 12(4):346-56. PubMed ID: 15985004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.